1 / 18

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

Ipilimumab Versus Placebo After <br />Complete Resection of Stage III Melanoma: <br />Initial Efficacy and Safety Results from the EORTC 18071 Phase III Trial. Presented By Alexander Eggermont at 2014 ASCO Annual Meeting. Slide 2. Presented By Alexander Eggermont at 2014 ASCO Annual Meeting.

finnea
Télécharger la présentation

Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ipilimumab Versus Placebo After <br />Complete Resection of Stage III Melanoma: <br />Initial Efficacy and Safety Results from the EORTC 18071 Phase III Trial Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  2. Slide 2 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  3. Slide 3 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  4. Immune Checkpoint Inhibitor Ipilimumab Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  5. EORTC 18071/CA184-029: Study Design Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  6. Key Eligibility Criteria Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  7. Slide 7 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  8. Baseline Patient Characteristics Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  9. Primary Endpoint: Recurrence-free Survival (IRC) Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  10. Recurrence-free Survival: Prespecified Subgroups Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  11. Slide 11 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  12. Slide 12 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  13. Time to Onset of Grade 2-5 irAEs Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  14. Slide 14 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  15. Slide 15 Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  16. Subgroup Analyses of RFS: Microscopic (N1) vs Clinically Palpable (N2) Lymph Nodes Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  17. Summary/Conclusions Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

  18. Acknowledgments Presented By Alexander Eggermont at 2014 ASCO Annual Meeting

More Related